(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/194093 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2025/020025

(22) International Filing Date:
14 March 2025 (14.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/566,145	15 March 2024 (15.03.2024)	US
63/667,476	03 July 2024 (03.07.2024)	US

(71) Applicant: **MORPHIC THERAPEUTIC, INC.** [US/US]; 35 Gatehouse Drive, A2, Waltham, MA 02451 (US).

(72) Inventors: **WANG, Hua**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **LIN, Fu-Yang**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **HUANG, Xinqiang**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **MAHMASSANI, Ziad**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **BABAOGLU, Kerim**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **MOY, Terence**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US). **PONDISH, Jessica**; c/o Morphic Therapeutic, Inc., 35 Gatehouse Drive, A2, Waltham, MA 02451 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INTEGRIN α7β1 ANTIBODIES AND USES THEREOF




FIG. 1A

(57) Abstract: The present disclosure provides, among other things, a class of antibodies or an antigen binding fragments that bind to calf-1 or calf-2 domain of α7β1 integrin. The anti-α7β1 antibodies of the present disclosure are effective in stabilizing the α7β1 integrin in the extended closed and extended-open conformations, which enhances the binding to laminins.

WO 2025/194093 A2

[Continued on next page]

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*